Literature DB >> 6273454

Determination of immunoglobulin M antibodies against hepatitis B core antigen and hepatitis A virus by reorienting sucrose gradient high-speed centrifugation for diagnosis of acute viral-hepatitis.

P D Swenson, M R Escobar, E A Galen, R L Carithers.   

Abstract

Immunoglobulin M (IgM) antibodies against hepatitis B core antigen (anti-HBc) and hepatitis A virus (anti-HAV) were determined in 41 cases of acute viral hepatitis. In sera positive for anti-HBc or anti-HAV, IgM was separated from IgG by reorienting sucrose gradient high-speed centrifugation, and the IgG- and IgM-containing serum fractions were tested for the presence of specific antibody by radioimmunoassay. At the onset of illness, 4 of the 41 cases were classified as hepatitis A, 31 were hepatitis B, and 6 were non-A, non-B hepatitis, based on the results of these tests and of assays for hepatitis B surface antigen and antibody and hepatitis B e antigen and antibody. Fourteen of these 41 patients (34%) required IgM anti-HBc or IgM anti-HAV testing or both for appropriate classification. IgM anti-HBc persisted for at least 7 weeks after onset but no longer than 17 weeks in all patients tested with transient hepatitis B surface antigen-positive acute hepatitis. IgM anti-HAV persisted up to but not longer than 62 days in the patients with hepatitis A. Therefore, IgM anti-HBc and IgM anti-HAV determinants are valuable tools for the differential diagnosis of acute A, B, and non-A, non-B hepatitis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6273454      PMCID: PMC273985          DOI: 10.1128/jcm.14.5.544-549.1981

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  The antibody response following hepatitis A infection.

Authors:  S A Locarnini; A A Ferris; N I Lehmann; I D Gust
Journal:  Intervirology       Date:  1977       Impact factor: 1.763

2.  Serodiagnosis of viral hepatitis A by a modified competitive binding radioimmunoassay for immunoglobulin M anti-hepatitis A virus.

Authors:  D W Bradley; H A Fields; K A McCaustland; J E Maynard; R H Decker; R Whittington; L R Overby
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

3.  Specific detection of IgM-antibodies by ELISA, applied in hepatitis-A.

Authors:  W Duermeyer; J van der Veen
Journal:  Lancet       Date:  1978-09-23       Impact factor: 79.321

Review 4.  Predictive value of markers of hepatitis virus infection.

Authors:  F Deinhardt
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

5.  Comparison of solid phase test systems for demonstrating antibodies against hepatitis A virus (anti-Hav) of the IgM-class.

Authors:  M Roggendorf; G G Frösner; F Deinhardt; R Scheid
Journal:  J Med Virol       Date:  1980       Impact factor: 2.327

6.  Solid-phase enzyme-linked immunosorbent assay for detection of hepatitis A-specific immunoglobulin M.

Authors:  S A Locarnini; A G Coulepis; A M Stratton; J Kaldor; I D Gust
Journal:  J Clin Microbiol       Date:  1979-04       Impact factor: 5.948

7.  IgM responses to hepatitis-A virus and hepatitis-B core antigen in acute and chronic liver disease in Malawi; possible role of non-A, non-B, hepatitis.

Authors:  E M Supran; M E Molyneux; J E Banatvala
Journal:  Trans R Soc Trop Med Hyg       Date:  1980       Impact factor: 2.184

8.  Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay.

Authors:  D W Bradley; J E Maynard; S H Hindman; C L Hornbeck; H A Fields; K A McCaustland; E H Cook
Journal:  J Clin Microbiol       Date:  1977-05       Impact factor: 5.948

9.  The IgM antibody responses to the core antigen of hepatitis B virus.

Authors:  B J Cohen
Journal:  J Med Virol       Date:  1978       Impact factor: 2.327

10.  Use of immunoglobulin M antibody to hepatitis B core antigen in diagnosis of viral hepatitis.

Authors:  R A Hawkes; C R Boughton; V Ferguson; N I Lehmann
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.